AbbVie Posts an Earnings Beat but Forecast Misses as Competition Intensifies
AbbVie says international sales of Humira in the fourth quarter fell 26.5% from a year earlier....…
175,240€
0,17%
Echtzeit-Aktienkurs Abbvie Inc.
Bid:
Ask:
Nachrichten zur Abbvie Inc. Aktie
AbbVie sets outlook below consensus amid generic threat to best selling drug
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie’s stock gains on Q4 results
Shares of AbbVie Inc. ABBV gained 2.4% in premarket trading on Thursday after the company beat earnings expectations for the…
Form 8-K AbbVie Inc. For: Feb 09
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results
Reports Full-Year Diluted EPS of $6.63 on a GAAP Basis, an Increase of 2.8 Percent; Adjusted Diluted EPS of $13.77,…
AbbVie Non-GAAP EPS of $3.60 beats by $0.02, revenue of $15.12B misses by $180M, initiates FY outlook
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie Q4 results in focus with eye on new drugs as Humira challengers enter US doors
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Earnings Previews: AbbVie, Cameco, Canopy Growth, PepsiCo, Under Armour
Before U.S. markets open on Thursday, AbbVie, Cameco, Canopy Growth, PepsiCo and Under Armour will report quarterly earnings....…
Teva follows AbbVie to leave top pharma industry group
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie pins hopes on newer drugs and deals to face Humira knockoffs – WSJ
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie Aims for New Drugs to Boost Sales as Competitors Target Humira
Drugmaker is turning to next-generation successors to Humira to replenish billions of dollars in sales that will be lost, and…
Zulassung von Medikamenten: Wie ein Pharmakonzern den Patentschutz bis zum Letzten ausreizt
Abbvie hat den Schutz für seinen Bestseller Humira jahrelang künstlich in die Länge gezogen und Milliarden damit verdient. Auch wegen…
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could…
AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?
AbbVie (ABBV) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Insights on the Facial Aesthetics Global Market to 2028 - Featuring AbbVie, Merz Pharma, Galderma and Candela Medical Among Others
DUBLIN, Jan. 31, 2023 /PRNewswire/ -- The "Global Facial Aesthetics Market Size, Share & Industry Trends Analysis Report By Product…
AbbVie (ABBV) Stock Moves -0.43%: What You Should Know
AbbVie (ABBV) closed at $145.65 in the latest trading session, marking a -0.43% move from the prior day....…
Insights on the HIV/AIDS Diagnostics Global Market to 2030 - Featuring Abbott Laboratories, Abbvie, Alere, Apogee Flow Systems and Beckman Coulter Among Others
DUBLIN, Jan. 30, 2023 /PRNewswire/ -- The "HIV/AIDS Diagnostics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key…
Emergency contraceptive pills market to grow by 3.72% Y-O-Y from 2022 to 2023: Rise in the number of initiatives to create awareness will drive growth -Technavio
NEW YORK, Jan. 30, 2023 /PRNewswire/ -- Emergency contraceptive pills market insights - Vendors: 15+, Including AbbVie Inc. | Afaxys…
How a Drug Company Made $114 Billion by Gaming the U.S. Patent System
AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is…
Lipid Based Formulations Global Market Report 2023: Featuring Novartis, AbbVie, F. Hoffmann-La Roche, Johnson & Johnson, Alnylam Pharmaceuticals & More
DUBLIN, Jan. 27, 2023 /PRNewswire/ -- The "Lipid Based Formulations Market - Global Industry Size, Share, Trends, Opportunity and Forecast,…
Global Psoriasis Therapeutics Market Report to 2031 - Featuring Abbvie, Amgen, Bausch Health, LEO Pharma and Novan Among Others
DUBLIN, Jan. 25, 2023 /PRNewswire/ -- The "Psoriasis Therapeutics Market By Drug Class, By Type, By Route of Administration: Global…
3 Reasons to Buy AbbVie and 2 Reasons Not to Buy
The pharmaceutical specialist is facing a pivotal year in 2023, thanks to growing competition....…
China Anti-Rheumatic Drug Markets Report 2022-2027 Featuring Pfizer, F. Hoffmann-La Roche, UCB S.A., Eli Lilly and Company, & AbbVie Inc.
DUBLIN, Jan. 24, 2023 /PRNewswire/ -- The "China Anti-Rheumatic Drug Market - Forecasts from 2022 to 2027" report has been…
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, AbbVie (ABBV) closed at $148.55, marking a -0.7% move from the previous day....…
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what…
Final Trades: Abbvie, Goldman Sachs, Charles River & more
The "Halftime Report" traders give their top picks to watch for the second half....…
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
In the latest trading session, AbbVie (ABBV) closed at $152.83, marking a -0.5% move from the previous day....…
SkinMedica® Launches Even & Correct
The Results Are Clear - A Scientifically Proven Path to Targeting the Appearance of Hyperpigmentation and Improving Skin Tone and…
Is AbbVie a Good Dividend Stock to Buy on the Dip?
The stock offers an attractive yield, but investors need to brace for declining revenue this year....…
BioMed X Extends Research Collaboration With AbbVie On Immunology And Tissue Engineering
WASHINGTON (dpa-AFX) - BioMed X, an independent German biomedical research institute, said that it has extended its ongoing research collaboration…
BioMed X, AbbVie extend partnership to focus on immunology research
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie and Lilly leave U.K. drug pricing deal
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Drugmakers Eli Lilly, AbbVie Leave UK Medicine-Pricing Agreement
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…
UPDATE 1-AbbVie, Eli Lilly exit UK drug pricing agreement
...(Adds details, background)
Jan 16 (Reuters) - Pharmaceutical......…
AbbVie, Eli Lilly exit UK drug pricing agreement
...(Reuters) - Pharmaceutical companies AbbVie and Eli Lilly have......…
Autoimmune Patient Perspective on the Corporate Reputation of Pharma Companies, 2021-2022: The Views of 293 Patient Groups - Pfizer Ranked 1st, AbbVie Ranked 2nd, Novartis Ranked 3rd
DUBLIN, Jan. 13, 2023 /PRNewswire/ -- The "The Corporate Reputation of Pharma in 2021- The Patient Perspective - Autoimmune Edition…
AbbVie: Alle Augen auf bevorstehenden Patentverlust - Aktienanalyse
Wien (www.aktiencheck.de) - AbbVie-Aktienanalyse von der Raiffeisen Bank International AG:
Benedikt-Luka Antic, Analyst der Raiffeisen Bank International AG (RBI), nimmt die…
Übernahme von Botox-Hersteller gibt AbbVie Schub
Frankfurt (Reuters) - Der US-Pharmakonzern AbbVie profitiert von einer hohen Nachfrage nach seinem Blockbuster-Medikament Humira und der Übernahme des Botox-Herstellers…
Agentur - Boehringer und AbbVie in Gesprächen über Krebs-Allianz
Bangalore (Reuters) - Deutschlands zweitgrößter Pharmakonzern Boehringer Ingelheim steht einem Agenturbericht zufolge vor einer umfassenden Partnerschaft bei Krebs-Therapien mit dem…